Daniel Loeb
Third Point
Daniel Loeb MEDICUS SCIENCES ACQUISITI-A stake
total: 588
Third Point MSAC trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2022 Q1
According to 2026 Q2 report, Daniel Loeb doesn't hold any MEDICUS SCIENCES ACQUISITI-A (MSAC) shares. To date, the estimated cost basis is nearly $9.65 for "buy" trades and estimated average "sell" price is $9.72. Third Point first purchased MSAC in 2021 Q2, initially acquiring 790,000 shares. Since the initial investment in MEDICUS SCIENCES ACQUISITI-A (MSAC), Third Point has made 1 more transaction.
When did Daniel Loeb sell MEDICUS SCIENCES ACQUISITI-A (MSAC)?
Daniel Loeb sold off the entire MEDICUS SCIENCES ACQUISITI-A (MSAC) position in 2022 Q1.
When did Daniel Loeb buy MEDICUS SCIENCES ACQUISITI-A (MSAC)?
Daniel Loeb first invested in MEDICUS SCIENCES ACQUISITI-A (MSAC) in 2021 Q2 at the reported quarter-end price of $9.65 per share.
What's the cost basis of Third Point's MSAC stake?
The estimated cost basis for MEDICUS SCIENCES ACQUISITI-A (MSAC) stake is around $9.65 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $9.65
- Weighted AVG sell price:
- $9.72
Daniel Loeb's historical trades in MEDICUS SCIENCES ACQUISITI-A
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q1
|
0.00%
|
0
|
$9.72
|
|
-100% (-790,000)
|
-0.05%
|
|
2021 Q2
|
0.04%
|
790,000
|
$9.65
|
$7,624,000
|
new
|
+0.04%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.